Search research articles
Contact Us
Filters
Showing results (11-20 of 23) with videos related to
Page
of 3
Sort By:
ERJ Open Research
|
June 10, 2026
Fenfluramine-associated pulmonary hypertension: a study of adverse events reporting system FAERS
Coline Brossat, Clément Jambon-Barbara, Alex Hlavaty, et al.
British Journal of Clinical Pharmacology
|
June 9, 2022
Identifying new drugs associated with pulmonary arterial hypertension: A WHO pharmacovigilance database disproportionality analysis
Alex Hlavaty, Matthieu Roustit, David Montani, et al.
Journal of Clinical Epidemiology
|
December 26, 2024
Priors and decision thresholds in phase 2 and phase 3 randomized controlled trials evaluating drug efficacy using Bayesian methods: a systematic review
Lorraine Barret, Léa Liaigre, Alex Hlavaty, et al.
Circulation
|
February 12, 2026
Second- and Third-Generation BCR-ABL Tyrosine Kinase Inhibitors and the Risk of Pulmonary Arterial Hypertension: A Prevalent New-User Design
Clément Jambon-Barbara, Samy Suissa, Sophie Dell'Aniello, et al.
ERJ Open Research
|
August 13, 2024
Development and validation of a code-based algorithm using in-hospital medical records to identify patients with pulmonary arterial hypertension in a French healthcare database
Clément Jambon-Barbara, Alex Hlavaty, Claire Bernardeau, et al.
American Journal of Respiratory and Critical Care Medicine
|
June 12, 2025
Detection and Evaluation of Drug-associated Pulmonary Arterial Hypertension
Clément Jambon-Barbara, Alex Hlavaty, Julien Grynblat, et al.
ERJ Open Research
|
November 26, 2025
Drugs and toxins associated with pulmonary arterial hypertension: from established culprits to novel threats
Julien Grynblat, Alex Hlavaty, Laurent Savale, et al.
Clinical Pharmacology and Therapeutics
|
November 7, 2025
Respiratory Disorders Associated with Antibody-Drug Conjugates: A Combined Analysis of the French and the WHO Pharmacovigilance Databases
Victor Mirleau, Alex Hlavaty, Etienne-Marie Jutant, et al.
The European Respiratory Journal
|
May 2, 2024
Characteristics and outcomes of patients developing pulmonary hypertension associated with proteasome inhibitors
Julien Grynblat, Charles Khouri, Alex Hlavaty, et al.
Chest
|
November 21, 2024
Association of Pulmonary Hypertension With Trastuzumab Emtansine: An Analysis of French Pulmonary Hypertension Registry and WHO Pharmacovigilance Database
Camille Poisson, Alex Hlavaty, Nicolas Favrolt, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 23) with videos related to
Sort By:
Page
of 3
ERJ Open Research
|
June 10, 2026
Fenfluramine-associated pulmonary hypertension: a study of adverse events reporting system FAERS
Coline Brossat, Clément Jambon-Barbara, Alex Hlavaty, et al.
British Journal of Clinical Pharmacology
|
June 9, 2022
Identifying new drugs associated with pulmonary arterial hypertension: A WHO pharmacovigilance database disproportionality analysis
Alex Hlavaty, Matthieu Roustit, David Montani, et al.
Journal of Clinical Epidemiology
|
December 26, 2024
Priors and decision thresholds in phase 2 and phase 3 randomized controlled trials evaluating drug efficacy using Bayesian methods: a systematic review
Lorraine Barret, Léa Liaigre, Alex Hlavaty, et al.
Circulation
|
February 12, 2026
Second- and Third-Generation BCR-ABL Tyrosine Kinase Inhibitors and the Risk of Pulmonary Arterial Hypertension: A Prevalent New-User Design
Clément Jambon-Barbara, Samy Suissa, Sophie Dell'Aniello, et al.
ERJ Open Research
|
August 13, 2024
Development and validation of a code-based algorithm using in-hospital medical records to identify patients with pulmonary arterial hypertension in a French healthcare database
Clément Jambon-Barbara, Alex Hlavaty, Claire Bernardeau, et al.
American Journal of Respiratory and Critical Care Medicine
|
June 12, 2025
Detection and Evaluation of Drug-associated Pulmonary Arterial Hypertension
Clément Jambon-Barbara, Alex Hlavaty, Julien Grynblat, et al.
ERJ Open Research
|
November 26, 2025
Drugs and toxins associated with pulmonary arterial hypertension: from established culprits to novel threats
Julien Grynblat, Alex Hlavaty, Laurent Savale, et al.
Clinical Pharmacology and Therapeutics
|
November 7, 2025
Respiratory Disorders Associated with Antibody-Drug Conjugates: A Combined Analysis of the French and the WHO Pharmacovigilance Databases
Victor Mirleau, Alex Hlavaty, Etienne-Marie Jutant, et al.
The European Respiratory Journal
|
May 2, 2024
Characteristics and outcomes of patients developing pulmonary hypertension associated with proteasome inhibitors
Julien Grynblat, Charles Khouri, Alex Hlavaty, et al.
Chest
|
November 21, 2024
Association of Pulmonary Hypertension With Trastuzumab Emtansine: An Analysis of French Pulmonary Hypertension Registry and WHO Pharmacovigilance Database
Camille Poisson, Alex Hlavaty, Nicolas Favrolt, et al.
Page
of 3